SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at aTyr Pharma

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options

If you suffered losses in aTyr and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

On Monday, September 15, 2025, aTyr Pharma, Inc. announced before the market opened that its EFZO-FIT study failed to meet its primary endpoint—the change from baseline in mean daily oral corticosteroid (OSC) dose at week 48—during an investor call.

The disappointing topline results triggered a sharp and immediate market sell-off. aTyr’s stock, which had closed at $6.03 per share on Friday, September 12, plunged to $1.02 per share by the close of trading on September 15, marking a single-day decline of approximately 83.2%.

To learn more about the ATyr Pharma investigation, go to www.faruqilaw.com/ATYR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.